Securities code: Wuxi Apptec Co.Ltd(603259) securities abbreviation: Wuxi Apptec Co.Ltd(603259) Announcement No.: pro 2022024
Announcement on the company’s external guarantee amount in 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important note: \uf020 information of the warrantee: all the warrantees are Wuxi Apptec Co.Ltd(603259) (hereinafter referred to as “the company”). The subsidiaries (hereinafter referred to as “subsidiaries”) within the scope of the consolidated statements with an estimated asset liability ratio of less than 70% in 2022 (calculated based on the latest audited data), including Shanghai Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd., Suzhou Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd Wuhan Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd., Tianjin Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd., Wuxi apptec (Hong Kong) Limited, Shanghai Hequan Pharmaceutical Co., Ltd., Wuxi Hequan Pharmaceutical Co., Ltd., Changzhou Hequan Life Science Co., Ltd., Changzhou Hequan Pharmaceutical Co., Ltd., Taixing Hequan Pharmaceutical Co., Ltd., Taixing Hequan Life Technology Co., Ltd., Shanghai Hequan pharmaceutical R & D Co., Ltd Nantong Wuxi Apptec Co.Ltd(603259) Pharmaceutical Technology Co., Ltd., Changshu Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd., wuxiapptecholding company, Inc., Wuxi advanced therapies Inc., Wuxi apptec, Inc.
Guarantee limit: provide the guaranteed party within the above scope with a total guarantee of no more than RMB 11.5 billion (hereinafter referred to as “this guarantee”). As of the disclosure date of this announcement, the company has no existing guarantee. \uf020 there is no counter guarantee in this guarantee, which needs to be deliberated and approved by the general meeting of shareholders of the company. \uf020 the company has no overdue guarantee.
1、 Overview of guarantee
In accordance with the company law of the people’s Republic of China and other relevant laws and regulations, the Listing Rules of the stock exchange where the company’s shares are listed, the Wuxi Apptec Co.Ltd(603259) articles of Association (hereinafter referred to as the “articles of association”) and the Wuxi Apptec Co.Ltd(603259) external guarantee management system, in order to meet the business and development needs of the company’s subsidiaries, In 2022, the company plans to provide subsidiaries with asset liability ratio of less than 70% (calculated based on the latest audited data) with a cumulative amount of no more than RMB
Guarantee of 11.5 billion yuan. The validity period of the guarantee limit is 12 months from the date of approval by the annual general meeting of shareholders in 2021 or until the date of deliberation and approval of the external guarantee limit in 2023 by the annual general meeting of shareholders in 2022 (whichever is shorter). The total amount of guarantee in 2022 includes the guarantee that the amount of a single guarantee occurred within the above validity period exceeds 10% of the net assets in the latest audited consolidated financial statements of the company. As of the disclosure date of this announcement, the company has no existing guarantee, and the total guarantee amount of the company in 2022 is the expected new guarantee amount in 2022, i.e. RMB 11.5 billion. Within the validity period of authorization, the guarantee balance at any time point shall not exceed the new guarantee amount of RMB 11.5 billion deliberated and approved by the general meeting of shareholders. The aforesaid guarantees are all between the company and its wholly-owned subsidiaries and holding subsidiaries, and the guarantee risk is controllable.
On the premise that the above-mentioned external guarantee amount is approved by the general meeting of shareholders of the company, the Finance Department of the company is further authorized to organize the implementation.
2、 Basic information of the guaranteed
The basic information of the above guaranteed is as follows:
1. Shanghai Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd
Main business: discovery and R & D services of small molecule drugs
Address: Building 1, No. 288, Fute Middle Road, China (Shanghai) pilot Free Trade Zone
Date of establishment: April 2, 2002
Legal representative: Tong Guodong
Main financial data: as of December 31, 2021, the total assets of the company are 25504783400 yuan, the total liabilities are 11469040200 yuan, and the net assets are 14035743200 yuan; In 2021, the company’s main business income was 45301886 million yuan and its net profit was 14193947 million yuan (Unaudited monomer caliber, unit: 10000 yuan).
The shareholding structure is a wholly-owned subsidiary of the company
2. Suzhou Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd
Main business: pharmacology, toxicology and safety evaluation research services
Address: No. 1318, Wuzhong Avenue, Wuzhong District, Suzhou
Date of establishment: October 8, 2006
Legal representative: Tong Guodong
Main financial data: as of December 31, 2021, the total assets of the company are 28562347 million yuan, the total liabilities are 14398898 million yuan and the net assets are 14163448 million yuan; In 2021, the company’s main business income was 16903334 million yuan and its net profit was 4385696 million yuan (Unaudited monomer caliber, unit: 10000 yuan).
The shareholding structure is a wholly-owned subsidiary of the company
3. Wuhan Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd. main business: discovery and R & D services of small molecule drugs
Address: No. 666, Gaoxin Avenue, Wuhan East Lake Development Zone
Date of establishment: November 12, 2010
Legal representative: Tong Guodong
Main financial data: as of December 31, 2021, the total assets of the company are 1839051200 yuan, the total liabilities are 1074054100 yuan, and the net assets are 764997100 yuan; In 2021, the company’s main business income was 1369706600 yuan and its net profit was 265270600 yuan (Unaudited monomer caliber, unit: 10000 yuan).
Ownership structure: a wholly-owned subsidiary of the company
4. Main business of Tianjin new drug development Co., Ltd
Address: No. 168, Nanhai Road, Tianjin Economic and Technological Development Zone
Date of establishment: June 5, 2006
Legal representative: Tong Guodong
Main financial data: as of December 31, 2021, the total assets of the company are 3339238300 yuan, the total liabilities are 1802960900 yuan, and the net assets are 1536277300 yuan;
In 2021, the company’s main business income was 2144765900 yuan and its net profit was 507994900 yuan (Unaudited monomer caliber, unit: 10000 yuan).
Ownership structure: a wholly-owned subsidiary of the company
5. Wuxiapptec (Hong Kong) Limited main business: business development and trade services
Domicile: flat / RM 826, 8 / F Ocean Centre, harbour city, 5 Canton Road, TST
Date of establishment: March 26, 2012
Main financial data: as of December 31, 2021, the total assets of the company are 94167544 million yuan, the total liabilities are 495345 million yuan, and the net assets are 44633044 million yuan; In 2021, the company’s main business income was 74927434 million yuan and its net profit was 2955434 million yuan (Unaudited monomer caliber, unit: 10000 yuan).
Ownership structure: a wholly-owned subsidiary of the company
6. Nantong Wuxi Apptec Co.Ltd(603259) Pharmaceutical Technology Co., Ltd. main business: pharmaceutical research and development
Address: No. 699, Huashi South Road, Qidong Economic Development Zone
Date of establishment: April 26, 2018
Legal representative: Tong Guodong
Main financial data: as of December 31, 2021, the total assets of the company are 1048739100 yuan, the total liabilities are 384853400 yuan, and the net assets are 663885800 yuan; In 2021, the company’s main business income was 4913464 million yuan and its net profit was 1124325 million yuan (Unaudited monomer caliber, unit: 10000 yuan). Ownership structure: a wholly-owned subsidiary of the company
7. Changshu Wuxi Apptec Co.Ltd(603259) new drug development Co., Ltd. main business: small molecule new drug research and development services
Address: No. 58, Haifeng Road, Haiyu Town, Changshu City
Date of establishment: November 11, 2019
Legal representative: Dong Jingchao
Main financial data: as of December 31, 2021, the total assets of the company are 7429772 million yuan, the total liabilities are 1967203 million yuan and the net assets are 5462569 million yuan; In 2021, the company’s main business income was 0 million yuan and its net profit was -154243 million yuan (Unaudited monomer caliber, unit: 10000 yuan).
Ownership structure: a wholly-owned subsidiary of the company
8. Wuxiapptec holding company, Inc. main business: investment consulting and investment management
Domicile: 615 South DuPont highway, Dover, Kent country, Delaware, 19901, US
Date of establishment: December 31, 2007
Main financial data: as of December 31, 2021, the total assets of the company are 2003410700 yuan, the total liabilities are 53 Hefei Meiya Optoelectronic Technology Inc(002690) 0 yuan, and the net assets are 1473383900 yuan; In 2021, the company’s main business income was 0 million yuan and its net profit was -3.3454 million yuan (Unaudited monomer caliber, unit: 10000 yuan).
The shareholding structure is a wholly-owned subsidiary of the company
9. Wuxiadvanced therapies Inc. main business: Overseas precision medical research and development services
Domicile: Corporation Trust Center, 1209 orange street, Wilmington, Delaware 19801, New Castle County, US
Date of establishment: June 26, 2019
Main financial data: as of December 31, 2021, the total assets of the company are 1892762600 yuan, the total liabilities are 1087370600 yuan, and the net assets are 805392000 yuan; In 2021, the company’s main business income was 870593900 yuan and its net profit was -1781144 million yuan (Unaudited monomer caliber, unit: 10000 yuan). The shareholding structure is a wholly-owned subsidiary of the company
10. Wuxiapptec, Inc. main business: medical device testing services and overseas precision medical R & D services
Domicile: 615 South DuPont highway, Dover, Kent country, Delaware, 19901, US
Date of establishment: November 26, 2002
Main financial data: as of December 31, 2021, the total assets of the company are 7206827 million yuan, the total liabilities are 3 Hua Xia Bank Co.Limited(600015) million yuan and the net assets are 3606812 million yuan; In 2021, the company’s main business income was 4548241 million yuan and its net profit was 102805 million yuan (Unaudited monomer caliber, unit: 10000 yuan). The shareholding structure is a wholly-owned subsidiary of the company
11. Shanghai Hequan Pharmaceutical Co., Ltd. main business: small molecule
